Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis.

Abstract

We aimed to analyze the efficacy and safety of romiplostim in the treatment of primary immune thrombocytopenia (ITP) in children. PubMed, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, Chinese biomedical literature database (CBM), Chinese Journal Full Text Database (CNKI), Wanfang and VIP database were searched. The bibliography was screened according to the inclusion and exclusion criteria and the target literature was selected. The data were extracted, and the quality of included literature was evaluated. RevMan 5.3 software was used to carry out the meta-analysis. The rate of effective, adverse and bleeding events was collected, and meta-analysis was performed. 3 out of 43 papers met the inclusion criteria. Meta-analysis showed that there was a statistical significance in effective rate and median time to platelet rise to response criteria of in romiplostim group, RR=5.05, [95% CI (2.21, 11.53), p<0.01] and RR=9.67, [95% CI (1.89, 49.46), p<0.01]. Similar results occurred in the rate of adverse event and serious adverse event, [RR=0.95, 95% CI (0.69,1.31), p>0.05] and [RR=1.65, 95% CI (0.53,5.31), p>0.05]; bleeding event of the two groups was similar [RR=1.27, 95% CI (0.92,1.75), p>0.05]. On the aspect of treating ITP, romiplostim is more effective and safer than placebo.